Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Viatris“
Suchtreffer
Begriffe & Kennungen
Ambrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · In a clinical study in healthy volunteers, steady-state dosing with ambrisentan 10 mg once daily did not signi
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · In vitro studies in rat hepatocytes also showed that ambrisentan did not induce Pgp, BSEP or MRP2 protein expr
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · In vitro, ambrisentan has no inhibitory effect on human transporters at clinically relevant concentrations, in
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Ketoconazole
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Oral contraceptives
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Other targeted PAH treatments
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Phosphodiesterase inhibitors
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Rifampicin
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Steady-state administration of ambrisentan in healthy volunteers had no clinically relevant effects on the sin
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Steady-state administration of ketoconazole (a strong inhibitor of CYP3A4) did not result in a clinically sign
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · Steady-state co-administration of ambrisentan and cyclosporine A resulted in a 2-fold increase in ambrisentan
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · The efficacy and safety of ambrisentan when co-administered with other treatments for PAH (e.g. prostanoids an
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · The potential for ambrisentan to induce CYP3A4 activity was explored in healthy volunteers with results sugges
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 Undesirable effects · 1
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · 8 System organ class Frequency Adverse reaction(s) Respiratory, thoracic and Very common Dyspnoea6, mediastina
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Decreased haemoglobin In the post-marketing period, cases of anaemia requiring blood cell transfusion have bee
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Description of selected adverse reactions
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Hepatic enzyme elevations (2%), hepatic injury and autoimmune hepatitis (including exacerbation of underlying
Eintrag öffnen